BRPI0416172A - polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal - Google Patents

polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal

Info

Publication number
BRPI0416172A
BRPI0416172A BRPI0416172-6A BRPI0416172A BRPI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A BR PI0416172 A BRPI0416172 A BR PI0416172A
Authority
BR
Brazil
Prior art keywords
ion
anion
binding
polymer
binding polymer
Prior art date
Application number
BRPI0416172-6A
Other languages
English (en)
Inventor
Eric Connor
Dominique Charmot
Han Ting Chang
Florence Roger
Gerrit Klearner
Son Hoal Nguyen
Original Assignee
Ilypsa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/701,385 external-priority patent/US7385012B2/en
Priority claimed from US10/806,495 external-priority patent/US7335795B2/en
Application filed by Ilypsa Inc filed Critical Ilypsa Inc
Publication of BRPI0416172A publication Critical patent/BRPI0416172A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F26/00—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F26/06—Homopolymers and copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a heterocyclic ring containing nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
    • C08G73/02—Polyamines
    • C08G73/0206—Polyalkylene(poly)amines
    • C08G73/0213—Preparatory process
    • C08G73/022—Preparatory process from polyamines and epihalohydrins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
    • C08L39/02—Homopolymers or copolymers of vinylamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

"POLìMERO LIGANTE A áNION, COMPOSIçãO FARMACêUTICA, POLìMEROS LIGANTES A FOSFATO E A ìONS, E, MéTODOS PARA MEDIR A INTERFERêNCIA à LIGAçãO AO ìON ALVO PARA UM POLìMERO LIGANTE A ìON, DE SELEçãO DE UM POLìMERO LIGANTE A ìONS QUE SE LIGAM A UM ìON ALVO, PARA MELHORIA DAS PROPRIEDADES TERAPêUTICAS E/OU ADEQUAçãO PARA ADMINISTRAçãO E/OU PROPRIEDADES FARMACêUTICAS DE UM POLìMERO POLIAMìNICO, DE FABRICAR UM POLìMERO LIGANTE A ìONS QUE SE LIGA A UM áNION ALVO, E DE REMOçãO DE UM áNION DE UM ANIMAL". Descrição de polímeros de ligantes (quelantes) de ânions. Em alguns casos, os polímeros ligantes a ânions são polímeros de baixo intumescimento. Em alguns casos, esses polímeros de ligação a ânions têm uma distribuição do volume de poros tal que uma fração do polímero não está disponível para solutos não interagentes maiores do que um dado percentual do peso molecular do íon alvo do polímero. Os polímeros ligantes a ânions são caracterizados pela baixa interferência na ligação de ânions quando essa interferência é medida, por exemplo, por meio de um pseudo-agente gastrintestinal, quando comparado com a mesma medida num tampão não interferente. A patente também descreve a composição farmacêutica, a metodologia de uso e kits.
BRPI0416172-6A 2003-11-03 2004-11-03 polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal BRPI0416172A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/701,385 US7385012B2 (en) 2003-11-03 2003-11-03 Polyamine polymers
US10/806,495 US7335795B2 (en) 2004-03-22 2004-03-22 Crosslinked amine polymers
US10/965,044 US7459502B2 (en) 2003-11-03 2004-10-13 Pharmaceutical compositions comprising crosslinked polyamine polymers
PCT/US2004/036745 WO2005041902A2 (en) 2003-11-03 2004-11-03 Anion-binding polymers and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0416172A true BRPI0416172A (pt) 2007-01-16

Family

ID=34557428

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416172-6A BRPI0416172A (pt) 2003-11-03 2004-11-03 polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal

Country Status (18)

Country Link
US (1) US7459502B2 (pt)
EP (5) EP1834976B1 (pt)
JP (3) JP3996944B2 (pt)
KR (1) KR101052581B1 (pt)
AT (5) ATE414730T1 (pt)
AU (1) AU2004285609B2 (pt)
BR (1) BRPI0416172A (pt)
CA (1) CA2542730C (pt)
CY (3) CY1107728T1 (pt)
DE (5) DE602004014527D1 (pt)
DK (3) DK2009042T3 (pt)
ES (4) ES2330693T3 (pt)
GB (1) GB2426248B (pt)
HK (1) HK1101697A1 (pt)
PL (3) PL1854826T3 (pt)
PT (3) PT1854826E (pt)
SI (3) SI2009042T1 (pt)
WO (2) WO2005041902A2 (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EA012798B1 (ru) * 2003-08-26 2009-12-30 Шир Холдингз Аг Фармацевтический состав, содержащий карбонат лантана (варианты)
US7381428B2 (en) * 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
US7767768B2 (en) * 2003-11-03 2010-08-03 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7608674B2 (en) * 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US7449605B2 (en) * 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7335795B2 (en) * 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US20060134225A1 (en) * 2004-10-15 2006-06-22 Moerck Rudi E Phosphate binder with reduced pill burden
US7985418B2 (en) 2004-11-01 2011-07-26 Genzyme Corporation Aliphatic amine polymer salts for tableting
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
WO2007022466A2 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Hyperphosphatemia in domestic animals: compositions and methods of treatment
AU2006279343A1 (en) * 2005-08-17 2007-02-22 Altairnano, Inc. Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
US8986669B2 (en) 2005-09-02 2015-03-24 Genzyme Corporation Method for removing phosphate and polymer used therefore
JP5113059B2 (ja) 2005-09-14 2013-01-09 ウイスコンシン アラムナイ リサーチ ファウンデーシヨン デンドリマーを含む組成物及びリン酸塩を結合するためのその使用
US8114393B2 (en) * 2005-09-14 2012-02-14 Wisconsin Alumni Research Foundation Methods and compositions for phosphate binding
WO2007035313A2 (en) * 2005-09-15 2007-03-29 Genzyme Corporation Sachet formulation for amine polymers
AU2012205214B2 (en) * 2005-09-15 2015-05-21 Genzyme Corporation Formulation for Amine Polymers
DE112006002618T5 (de) * 2005-09-30 2008-08-28 Ilypsa Inc., Santa Clara Verfahren und Zusammensetzungen zum selektiven Entfernen von Kaliumionen aus dem Gastrointestinaltrakt eines Säugers
EP1928433A2 (en) * 2005-09-30 2008-06-11 Ilypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
DK1973529T3 (da) * 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
US20070177866A1 (en) * 2006-01-31 2007-08-02 Yoshizo Fujimoto Camera extension arm
JP2009526840A (ja) * 2006-02-14 2009-07-23 テバ ファーマシューティカル インダストリーズ リミティド 脂肪族アミンポリマーの医薬製剤及びそれらの製造方法
CN100398112C (zh) * 2006-03-24 2008-07-02 辽宁诺康生物制药有限责任公司 一种治疗血磷酸盐过多症的药物及其制备方法
US20080085259A1 (en) * 2006-05-05 2008-04-10 Huval Chad C Amine condensation polymers as phosphate sequestrants
WO2008011047A2 (en) * 2006-07-18 2008-01-24 Genzyme Corporation Amine dendrimers
US7964182B2 (en) * 2006-09-01 2011-06-21 USV, Ltd Pharmaceutical compositions comprising phosphate-binding polymer
RU2009111853A (ru) * 2006-09-01 2010-10-10 Юсв Лимитед (In) Способ получения гидрохлорида севеламера и его лекарственной формы
JP2010504975A (ja) 2006-09-29 2010-02-18 ゲンズイメ コーポレーション アミドデンドリマー組成物
BRPI0720234A2 (pt) 2006-12-14 2013-12-24 Genzyme Corp Composição farmacêutica
WO2008103368A1 (en) * 2007-02-23 2008-08-28 Genzyme Corporation Amine polymer compositions
EP2131820A1 (en) * 2007-03-08 2009-12-16 Genzyme Corporation Sulfone polymer compositions
US20100166696A1 (en) * 2007-04-27 2010-07-01 Dhal Pradeep K Amido-amine dendrimer compositions
AU2008273278A1 (en) * 2007-07-11 2009-01-15 Toray Industries, Inc. Crosslinked polyallylamine or acid addition salt thereof, and use thereof for medical purposes
EP2016947A1 (en) * 2007-07-17 2009-01-21 Chemo Ibérica, S.A. Novel one step process for preparing cross-linked poly(allylamine) polymers
WO2009023544A2 (en) * 2007-08-10 2009-02-19 Ilypsa, Inc. Dosage unit anion-exchange polymer pharmaceutical compositions
WO2009034540A1 (en) * 2007-09-11 2009-03-19 Ranbaxy Laboratories Limited Pharmaceutical composition of sevelamer
JP5332520B2 (ja) * 2007-11-07 2013-11-06 アステラス製薬株式会社 医薬用錠剤
WO2009097127A1 (en) * 2008-01-31 2009-08-06 Genzyme Corporation Pharmaceutical compositions
WO2009154747A1 (en) * 2008-06-20 2009-12-23 Genzyme Corporation Pharmaceutical compositions
US20110081413A1 (en) * 2009-01-22 2011-04-07 Ashok Omray Pharmaceutical Compositions Comprising Phosphate-Binding Polymer
IT1394299B1 (it) * 2009-05-12 2012-06-06 Chimico Internaz Spa Lab Procedimento per la preparazione di sevelamer
EP2539389B1 (en) * 2010-02-24 2017-12-20 Relypsa, Inc. Amine polymers for use as bile acid sequestrants
ES2549513T3 (es) * 2010-02-24 2015-10-28 Relypsa, Inc. Polivinilamina, polialilamina y polietilenimina reticuladas para uso como secuestradores de ácidos biliares
ES2598500T3 (es) * 2010-02-24 2017-01-27 Relypsa, Inc. Poliimidazoles para su uso como secuestrantes de ácidos biliares
EP3848040A1 (en) 2010-05-12 2021-07-14 Spectrum Pharmaceuticals, Inc. Lanthanum dioxycarbonate and use
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9302922B2 (en) 2012-01-30 2016-04-05 California Institute Of Technology Filtration membranes and related compositions, methods and systems
US10369529B2 (en) 2012-01-30 2019-08-06 California Institute Of Technology Mixed matrix membranes with embedded polymeric particles and networks and related compositions, methods, and systems
EP2557074A1 (en) 2011-08-11 2013-02-13 Astellas Pharma Inc. Process for the preparation of N,N,N',N'-tetrakis(3-aminopropyl)-1,4-butanediamine
CN104640906B (zh) 2012-07-19 2016-11-23 佐治亚-太平洋化工品有限公司 来自新的交联剂的高效湿强度树脂
WO2014150873A1 (en) * 2013-03-15 2014-09-25 Genzyme Corporation Sequestrants of advanced glycation end product (age) precursors
PL3003327T3 (pl) 2013-06-05 2018-02-28 Tricida Inc. Protono-wiążące polimery do podawania doustnego
US10435528B2 (en) 2013-09-17 2019-10-08 Aquanano Llc High-capacity anion exchange materials
JP5843986B2 (ja) * 2014-03-25 2016-01-13 アステラス製薬株式会社 粒状医薬組成物
WO2016043808A1 (en) 2014-09-17 2016-03-24 Aquanano Llc High-capacity anion exchange material
AU2015360413B2 (en) 2014-12-10 2021-07-08 Tricida, Inc. Proton-binding polymers for oral administration
KR20170134572A (ko) * 2015-04-06 2017-12-06 쓰리엠 이노베이티브 프로퍼티즈 컴파니 제거가능한 필름 형성 겔 조성물 및 이의 적용 방법
CN107683357A (zh) * 2015-05-29 2018-02-09 艺康美国股份有限公司 源自新型交联剂的高效湿强度树脂
JP7071284B2 (ja) * 2016-05-06 2022-05-18 トリシダ・インコーポレイテッド 酸塩基障害を処置するためのＨＣｌ結合性組成物およびその方法
KR20190084125A (ko) 2016-12-28 2019-07-15 후지필름 가부시키가이샤 질소 원자 함유 폴리머 또는 그 염의 유화액, 그 제조 방법, 및 입자의 제조 방법
CN107141408A (zh) * 2017-06-12 2017-09-08 厦门建霖健康家居股份有限公司 一种抗菌聚合物及其制备方法
US10934380B1 (en) 2017-09-25 2021-03-02 Tricida, Inc. Crosslinked poly(allylamine) polymer pharmaceutical compositions
TW201922268A (zh) 2017-10-16 2019-06-16 日商富士軟片股份有限公司 高磷血症治療劑及粒子
EP3698799B1 (en) * 2017-10-16 2022-01-26 FUJIFILM Corporation Hyperphosphatemia treatment agent
CA3080651A1 (en) 2017-11-03 2019-05-09 Tricida, Inc. Compositions for and method of treating acid-base disorders
CN111521705B (zh) * 2020-05-05 2021-04-20 大连润生康泰医学检验实验室有限公司 一种血清中胆汁酸的富集方法
WO2023064357A1 (en) * 2021-10-13 2023-04-20 Tricida, Inc. Pharmaceutical compositions for the treatment of lithiasis disorders
CN115260355A (zh) * 2022-05-16 2022-11-01 江苏中天药业有限公司 一种阴离子交换树脂、其制备方法、该树脂与药物的复合物和其掩味制剂

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US814789A (en) 1904-12-21 1906-03-13 Edward D Mackintosh Drawing and plotting device.
US3308020A (en) 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3499960A (en) 1965-01-25 1970-03-10 Merck & Co Inc Palatable coated particles of an anion exchange resin
US3692895A (en) 1970-09-08 1972-09-19 Norman A Nelson Method of reducing hypercholesteremia in humans employing a copolymer of polyethylenepolyamine and a bifunctional substance, such as epichlorohydria
US3974272A (en) 1972-09-01 1976-08-10 Merck & Co., Inc. Palatable cholestyramine coacervate compositions
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
US3930810A (en) 1974-07-31 1976-01-06 Universal Oil Products Company Additives for petroleum distillates
US4015939A (en) 1976-05-12 1977-04-05 Bio-Rad Laboratories, Inc. Competitive binding thyroid assay with improved bound-free separation step
US4135880A (en) 1977-08-19 1979-01-23 Bio-Rad Laboratories, Inc. Folate assay with ion exchange resin bound-free separation
US4410688A (en) 1981-04-29 1983-10-18 Allied Corporation Macromolecular highly branched homogeneous compound
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
JPS6090243A (ja) 1983-10-25 1985-05-21 Nitto Boseki Co Ltd 小球状モノアリルアミン橋かけ重合体の製造方法
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4599400A (en) 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
US4747881A (en) 1985-02-05 1988-05-31 Warner-Lambert Company Ingestible aggregate and delivery system prepared therefrom
US4734200A (en) 1986-04-04 1988-03-29 Advanced Separation Technologies Incorporated Process for removal of fluoride and phosphorus-type contaminants from acidic wastewater
IT1190349B (it) 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5807582A (en) 1988-08-26 1998-09-15 Pharmacia & Upjohn Company Fine-beaded colestipol hydrochloride and pharmaceutically elegant dosage forms made therefrom
GB8829088D0 (en) 1988-12-13 1989-01-25 Smith Kline French Lab Compounds
US5091175A (en) 1990-05-14 1992-02-25 Erbamont Inc. Pharmaceutical composition containing bile acid sequestrant enclosed in a size-exclusion membrane
FR2680791B1 (fr) 1991-08-30 1994-09-09 Bp Chemicals Snc Procede de fabrication d'un polymere reticule et utilisation du polymere.
BE1007260A3 (nl) 1993-07-08 1995-05-02 Dsm Nv Werkwijze voor het bereiden van een dendritisch macromolekuul.
US5530092A (en) 1992-01-13 1996-06-25 Dsm N.V. Dendritic macromolecule and the preparation thereof
US5380522A (en) 1992-08-11 1995-01-10 Day; Charles E. Method for treatment of irritable bowel syndrome
US5451397A (en) * 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
DE69410995T2 (de) 1993-02-17 1998-11-05 British Tech Group 1 guanidino gruppen enthaltende polymere zur verwendung in der therapie
US5487888A (en) 1993-05-20 1996-01-30 Geltex, Inc. Iron-binding polymers for oral administration
US5607669A (en) 1994-06-10 1997-03-04 Geltex Pharmaceuticals, Inc. Amine polymer sequestrant and method of cholesterol depletion
US6129910A (en) 1993-06-02 2000-10-10 Geltex Pharmaceuticals, Inc. Water-insoluble noncrosslinked bile acid sequestrants
US5618530A (en) 1994-06-10 1997-04-08 Geltex Pharmaceuticals, Inc. Hydrophobic amine polymer sequestrant and method of cholesterol depletion
CA2129079C (en) 1993-08-03 2006-01-17 Tatsuo Nomura Orally administrable cholesterol lowering agent
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5667775A (en) 1993-08-11 1997-09-16 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
US5414068A (en) 1994-01-24 1995-05-09 Rohm And Haas Company Crosslinked anion exchange particles and method for producing the particles
JPH09508170A (ja) 1994-01-28 1997-08-19 デーエスエム ナムローゼ フェンノートシャップ 樹枝状高分子物質およびその製造法
BE1008134A3 (nl) 1994-03-16 1996-01-23 Dsm Nv Bereiding van stervormig vertakte polymeren.
TW474813B (en) 1994-06-10 2002-02-01 Geltex Pharma Inc Alkylated composition for removing bile salts from a patient
GB9503061D0 (en) 1995-02-16 1995-04-05 British Tech Group Polymeric compounds
US6060604A (en) 1995-03-31 2000-05-09 Florida State University Pharmaceutical compounds comprising polyamines substituted with electron-affinic groups
NL1001973C2 (nl) 1995-12-21 1997-06-24 Stork Friesland Bv Semipermeabel composietmembraan.
ES2162658T3 (es) 1996-03-05 2002-01-01 Mitsubishi Chem Corp Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia.
US6034129A (en) 1996-06-24 2000-03-07 Geltex Pharmaceuticals, Inc. Ionic polymers as anti-infective agents
US6180094B1 (en) 1996-07-19 2001-01-30 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
JP4358303B2 (ja) 1996-10-23 2009-11-04 ダウ グローバル テクノロジーズ インコーポレイティド 食物ホスフェート又はオキサレート吸収を低下させるための水溶性ポリマー
JP2003183168A (ja) * 1997-04-04 2003-07-03 Chugai Pharmaceut Co Ltd リン酸結合性ポリマー含有製剤
TW592727B (en) 1997-04-04 2004-06-21 Chugai Pharmaceutical Co Ltd Phosphate-binding polymer preparations
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US6007803A (en) 1997-09-19 1999-12-28 Geltex Pharmaceuticals, Inc. Ionic polymers as toxin binding agents
US20040170600A1 (en) 1997-10-22 2004-09-02 Jaime Simon Water-soluble polymers for the reduction of dietary phosphate or oxalate absorption
US6726905B1 (en) 1997-11-05 2004-04-27 Genzyme Corporation Poly (diallylamines)-based phosphate binders
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
US6566407B2 (en) 1997-11-05 2003-05-20 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
HUP0100469A2 (hu) 1997-12-19 2001-08-28 Smithkline Beecham Corporation Eljárás harapással diszpergálható tabletták előállítására
US6333051B1 (en) 1998-09-03 2001-12-25 Supratek Pharma, Inc. Nanogel networks and biological agent compositions thereof
JP3363143B2 (ja) * 1998-10-12 2003-01-08 中外製薬株式会社 リン酸結合性ポリマー粒子
TW568788B (en) 1998-10-12 2004-01-01 Chugai Pharmaceutical Co Ltd Polymer combining with phosphoric acid and preparation containing the same
US6361768B1 (en) 1998-12-29 2002-03-26 Pmd Holdings Corp. Hydrophilic ampholytic polymer
US6180754B1 (en) 1999-09-03 2001-01-30 The Dow Chemical Company Process for producing cross-linked polyallylamine polymer
US6362266B1 (en) 1999-09-03 2002-03-26 The Dow Chemical Company Process for reducing cohesiveness of polyallylamine polymer gels during drying
US20020054903A1 (en) 1999-10-19 2002-05-09 Joseph Tyler Direct compression polymer tablet core
US6733780B1 (en) 1999-10-19 2004-05-11 Genzyme Corporation Direct compression polymer tablet core
AU2001241077A1 (en) 2000-03-09 2001-09-17 Hisamitsu Pharmaceutical Co. Inc. Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same
DE10011481A1 (de) 2000-03-09 2001-10-18 Fresenius Hemocare Gmbh Adsorbens zum Absenken der Konzentration von Fibrinogen und/oder Fibrin, Verwendung des Adsorbens zur Herstellung eines Adsorbers und Adsorber mit dem Adsorbens
US20040059065A1 (en) 2000-03-09 2004-03-25 Takeshi Goto Crosslinked anion-exchange resin or salt thereof
EP1283046A1 (en) 2000-03-13 2003-02-12 Hisamitsu Pharmaceutical Co., Inc. Preventives and/or remedies for hyperphosphatemia
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
MY133977A (en) 2000-06-16 2007-11-30 Nippon Catalytic Chem Ind Crosslinked polymers containing tertiary amine and/or quaternary ammonium salt structures, processes for making and uses thereof
CA2428800C (en) 2000-11-20 2011-09-13 Dow Global Technologies Inc. In vivo use of fluid absorbent polymers
US6710162B2 (en) 2001-02-16 2004-03-23 Genzyme Corporation Method of drying a material having a cohesive phase
CN1511039A (zh) 2001-04-18 2004-07-07 ԭ���ø� 降低血浆葡萄糖的方法
AU2002257147B9 (en) 2001-04-18 2005-08-18 Genzyme Corporation Methods of treating syndrome X with aliphatic polyamines
WO2002085379A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for improving vascular access in patients with vascular shunts
WO2002085380A1 (en) 2001-04-18 2002-10-31 Geltex Pharmaceuticals, Inc. Method for treating gout and reducing serum uric acid
WO2002085383A1 (en) 2001-04-18 2002-10-31 Genzyme Corporation Method for reducing copper levels and treating copper toxicosis
ATE380553T1 (de) 2001-04-18 2007-12-15 Genzyme Corp Aminpolymere zur behandlung von gicht und zur senkung des harnsäuregehaltes
US6600011B2 (en) 2001-10-09 2003-07-29 Genzyme Corporation Process for purification and drying of polymer hydrogels
JP3931639B2 (ja) * 2001-11-19 2007-06-20 セイコーエプソン株式会社 インクジェットプリンタに使用するための水性インク組成物
AU2003282867A1 (en) 2002-10-22 2004-05-13 Genzyme Corporation Amine polymers for promoting bone formation
DE10305807A1 (de) 2003-02-12 2004-08-26 Basf Ag Polymethylenamine und Verfahren zu deren Herstellung
US7449605B2 (en) 2003-11-03 2008-11-11 Ilypsa, Inc. Crosslinked amine polymers
US7459502B2 (en) * 2003-11-03 2008-12-02 Ilypsa, Inc. Pharmaceutical compositions comprising crosslinked polyamine polymers
US7385012B2 (en) 2003-11-03 2008-06-10 Ilypsa, Inc. Polyamine polymers
US7335795B2 (en) 2004-03-22 2008-02-26 Ilypsa, Inc. Crosslinked amine polymers
US7608674B2 (en) 2003-11-03 2009-10-27 Ilypsa, Inc. Pharmaceutical compositions comprising cross-linked small molecule amine polymers
US20050276781A1 (en) 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use

Also Published As

Publication number Publication date
DK1854826T3 (da) 2009-01-12
EP1682606A4 (en) 2006-12-20
DE602004017918D1 (de) 2009-01-02
GB2426248A (en) 2006-11-22
CY1107728T1 (el) 2013-04-18
EP1682606B1 (en) 2007-06-06
EP1834976B1 (en) 2012-02-22
EP2009042A1 (en) 2008-12-31
JP5074838B2 (ja) 2012-11-14
GB0610607D0 (en) 2006-07-05
ATE445662T1 (de) 2009-10-15
ATE414730T1 (de) 2008-12-15
JP2007146180A (ja) 2007-06-14
PL1854826T3 (pl) 2009-06-30
JP3996944B2 (ja) 2007-10-24
EP2009042B1 (en) 2009-10-14
PT2009042E (pt) 2009-10-23
ATE364057T1 (de) 2007-06-15
EP1687349A4 (en) 2006-12-27
AU2004285609B2 (en) 2009-04-23
US20050131138A1 (en) 2005-06-16
WO2005041900A2 (en) 2005-05-12
PT1682606E (pt) 2007-09-05
JP2007262421A (ja) 2007-10-11
AU2004285609A1 (en) 2005-05-12
WO2005041902A2 (en) 2005-05-12
DE602004023661D1 (de) 2009-11-26
PL1682606T3 (pl) 2007-10-31
ES2287806T3 (es) 2007-12-16
DK1682606T3 (da) 2007-10-01
DK2009042T3 (da) 2009-11-30
ATE398636T1 (de) 2008-07-15
KR101052581B1 (ko) 2011-07-29
JP2007510783A (ja) 2007-04-26
EP1834976A1 (en) 2007-09-19
KR20070026338A (ko) 2007-03-08
CY1110562T1 (el) 2015-04-29
ES2330693T3 (es) 2009-12-14
HK1101697A1 (en) 2007-10-26
EP1687349B1 (en) 2008-06-18
CA2542730A1 (en) 2005-05-12
CA2542730C (en) 2012-07-10
WO2005041900A3 (en) 2006-06-08
SI2009042T1 (sl) 2009-12-31
CY1110475T1 (el) 2015-04-29
PL2009042T3 (pl) 2010-05-31
DE112004002099T5 (de) 2007-01-04
DE602004006892T2 (de) 2008-02-07
DE602004014527D1 (de) 2008-07-31
JP4902864B2 (ja) 2012-03-21
EP1682606A2 (en) 2006-07-26
EP1854826B1 (en) 2008-11-19
GB2426248B (en) 2008-08-13
WO2005041902A3 (en) 2006-05-18
ATE546482T1 (de) 2012-03-15
PT1854826E (pt) 2008-12-15
DE602004006892D1 (de) 2007-07-19
EP1687349A2 (en) 2006-08-09
SI1682606T1 (sl) 2007-10-31
ES2308294T3 (es) 2008-12-01
US7459502B2 (en) 2008-12-02
ES2318823T3 (es) 2009-05-01
SI1854826T1 (sl) 2009-06-30
EP1854826A1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
BRPI0416172A (pt) polìmero ligante a ánion, composição farmacêutica, polìmeros ligantes a fosfato e a ìons, e, métodos para medir a interferência à ligação ao ìon alvo para um polìmero ligante a ìon, de seleção de um polìmero ligante a ìons que se ligam a um ìon alvo, para melhoria das propriedades terapêuticas e/ou adequação para administração e/ou propriedades farmacêuticas de um polìmero poliamìnico, de fabricar um polìmero ligante a ìons que se liga a um ánion alvo, e de remoção de um ánion de um animal
Natale et al. Ion release and mechanical properties of calcium silicate and calcium hydroxide materials used for pulp capping
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
BR9811524A (pt) Tensoativos de alquilarilsulfonato aperfeiçoados
BRPI0510716A (pt) uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit
Corby et al. Decreased alpha-adrenergic receptors in newborn platelets: cause of abnormal response to epinephrine
BRPI0415448A (pt) método de alvejar populações de célula especìfica empregando-se conjugados de maytansinoid de agente de ligação celular ligados por meio de um ligante não-clivável, os referidos conjugados, e métodos de preparação dos referidos conjugados
Murata et al. Dimensional stability and weight changes of tissue conditioners
BR0210720A (pt) Composto e uso do mesmo
CA2798562A1 (en) Methods and compositions for the diagnosis and treatment of thyroid cancer
Marinov et al. Intra‐and interlaboratory variability of Paroxysmal Nocturnal Hemoglobinuria testing by flow cytometry following the 2012 practical guidelines for high‐sensitivity paroxysmal nocturnal hemoglobinuria testing
Wen et al. Real-world evidence of ABVD-like regimens compared with ABVD in classical Hodgkin lymphoma: A 10-year study from China
Kalman et al. Renal tubular function in children with β‐thalassemia minor
Alovero et al. Mode of action of sulfanilyl fluoroquinolones
ATE240985T1 (de) Flammfeste polyvinylarenzusammensetzungen
Larsson et al. On the binding of the bisquaternary ammonium compound paraquat to melanin and cartilage in vivo
Müller et al. The influence of different combinations of Eucalyptus saligna and Pinus taeda veneers in LVL panels
BR112015002194A2 (pt) dispositivo de fixação de osso que compreende pelo menos uma placa e um conjunto de parafusos produzido a partir de materiais reabsorvíveis
BR9814676A (pt) éteres de celulose contendo grupos butenila e seu uso como colóides protetores para polimerização
Zhao et al. Twenty-four-hour urine osmolality should be used in combination with other urine parameters in urolithiasis patients
BR112018016728A2 (pt) estabilizadores para melhorar a estabilidade de armazenamento de formulações secas de material de construção contendo pó de polímero
RU2021101319A (ru) Составы и способы для воздействия на впв
Burns A non-carcinogenic substrate for immunoperoxidase procedures.
NEMATI et al. 323 A COMPARISON OF THE DIAMETRAL TENSILE STRENGTH (DTS) OF FUJI TYPE II AND SDS GLASS IONOMER CEMENTS (IN-VITRO STUDY)
BRMU8501313U (pt) Aperfeiçoamentos em amortecedor separador de alumìnio injetado para linhas de alta tensão (maior que 200 kv)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.